Relmada Therapeutics(NASDAQ) RLMD

Relmada Therapeutics helps people fighting aggressive bladder cancer and rare brain-related disorders. The company creates medicines that deliver treatment more effectively to the body. These products aim to improve life for patients with difficult-to-treat conditions.

From Bladder Cancer to Brain Health

• NDV-01: Long-acting treatment for non-muscle-invasive bladder cancer, which is cancer found in the inner lining of the bladder. It uses a specialized delivery system to release medication slowly over 10 days.
• Sepranolone: Injectable medicine for central nervous system diseases, which are disorders affecting the brain and spinal cord. It targets specific receptors to help reduce compulsive behaviors seen in conditions like Tourette Syndrome.

A Major Strategy Shift

• Acquired the rights to sepranolone from Asarina Pharma AB in February 2025 for a total price of 3 million euros.
• Licensed the cancer drug NDV-01 from Trigone Pharma Ltd in March 2025 for an upfront payment of $3.5 million.
• Terminated the development of its former lead depression drug, esmethadone, in July 2025 after a strategic review.
• Ended a research agreement with Arbormentis LLC for a metabolic disease treatment in May 2025 to focus on new candidates.

Smarter Drug Delivery

Relmada uses a specialized technology that allows chemotherapy to stay inside the bladder for up to 10 days. This long-acting approach replaces traditional methods that require patients to stay in a clinic for several hours per dose.

The Financial Picture

• Operating cash flow reached $31.2 million in Q4 2025, improving 454.5% from a $8.8 million loss in Q4 2024.
• Net loss reached $19.9 million in Q4 2025, deepening 6.5% from the $18.7 million loss in Q4 2024.
• Operating income was a loss of $20.3 million in Q4 2025, worsening 6.6% from the $19.1 million loss in Q4 2024.
• Market capitalization grew to $329.7 million in Q4 2025, up 2001.1% from $15.7 million in Q4 2024.

Bottom Line

Relmada has completely transformed its business by moving away from its original focus on depression treatments. The company is now dedicated to developing newly acquired candidates for bladder cancer and rare neurological diseases.